Caredx Inc (CDNA)

NASD · Healthcare · Diagnostics & Research · USA

Caredx Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.

CareDx develops diagnostic testing and digital solutions for transplant patients and centers. The company offers blood-based tests to detect organ rejection in heart, kidney, and lung recipients, along with pre-transplant products and pharmacy services. Operating laboratories in California, Nebraska, and Sweden, CareDx serves transplant facilities across the United States and Europe.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Caredx Inc stock.

Our verdict on CDNA

Overvalued: intrinsic value $41.64 per share, market price $74.56, margin of safety -79.1% (as of 2026-11-17).

A 4.0x revenue multiple, discounted for its losses, values the shares at $41.64; the price of $74.56 is 79% above that value.

ETFs with the most weight in CDNA

17 more funds hold it; the full list is part of the paid plan.

More on CDNA

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than CDNA in Diagnostics & Research

5 more in this industry show a wider margin of safety.

Is CDNA undervalued or overvalued?

CDNA is overvalued (as of the 2026-11-17 close). A 4.0x revenue multiple, discounted for its losses, values the shares at $41.64; the price of $74.56 is 79% above that value.

What is the intrinsic value of CDNA?

$41.64 per share (as of the 2026-11-17 close), against a market price of $74.56. That is a margin of safety of -79.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.